The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

From the quarter under review, a change has been made in respect to the impact of exchange rate fluctuations pertaining to changes in SG&A expenses, which are now included under exchange rate ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

Analysis of Hawaiian Electric's Q3 performance: a loss of $0.91/share due to wildfire liabilities, settlement agreements, and strategic review of clean energy subsidiary.

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

"The launch of the DREAM completes our vision of the Lupus Nexus," said Devon Kelly, Director, Lupus Nexus, Lupus Research ...

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis ...